Answers are grounded in this paper and cite their sources.
T HE beta-emi t t ing radioact ive isotopes provide lesions of predictable size in neural tissue. 1-~ The range of these particles is cons tan t for each par t icular isotope. The dose delivered depends upon the rate of emission, the distance from the source, and the dura t ion of contac t with the tissue. As the ac t iv i ty of the source m a y be kept constant , the size of the lesion can be controlled accura te ly (up to its max imum) by vary ing the dura t ion of contact . This clinical simplicity is somewhat offset by the inconveniences of obta ining f rom a nuclear reactor a new supply of isotope for each clinical application, for it is the rule t ha t those isotopes with the more penet ra t ing beta emissions have the shorter halflives. There is, however, one useful combination, s t ront ium-90 and yt t r ium-90. Stront ium-90 is one of the more a b u n d a n t fission p roduc t s of uranium-~35. I t ordinarily is no t available in isotopically pure form because of con tamina t ion with other stable fission products of s t ront ium. The max i mum available specific ac t iv i ty is about one-third the theoretical value of 145 curies per gram. St ront ium-90 decays with a ~8-year half-life by emission of a beta particle of modera te energy (Em~x~0.54 M E V ) to y t t r ium-90 which decays in tu rn to zirconium-90 with a half-life of ~.67 days by emission of a highenergy be ta particle (E~a,~-~2.~7 M E V ) which has a range of about 11 ram. in water. Thus a Srg~ 9~ source delivers a high-energy beta on a vi r tual ly pe rmanen t basis. I t s long
No takes yet. Share an insight, caveat, or question.
Mullan et al. (1963) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: